How Cultured Chicken is Made

A Deep Dive into Cellular Agriculture Production

This page provides background for The Unjournal’s upcoming expert workshop on CM production costs. We’re bringing together TEA researchers, evaluators, and stakeholders to assess cost trajectories and identify key uncertainties. Join us

For substantive debate on biology, costs, or welfare — please post on 💬 GitHub Discussions. That’s where threaded conversation can get involved, with replies others can reply to and build on. Direct links:

  • 🧠 Substantive hub — for biology, economics, engineering, and welfare debate (the main event)
  • 🎯 PQ framing hub — for how we define the questions (jurisdiction forks, resolution criteria)
  • 💬 Workshop hub — for session prep, agenda, and logistics
  • 📖 Full Discussion Map — the curated index

For quick inline notes on specific text, use Hypothesis (click the < tab on the right edge). For anything beyond a brief highlight, prefer GitHub Discussions so the conversation stays organized.

Tip

Return to: Interactive Cost Model | Technical details: Documentation | Workshop (May 2026)

Audio overview(AI-generated · note)
How Cultured Meat is Made ~11 min

Overview

Cultured chicken (also called “cell-based” or “cultivated” chicken) is produced by growing avian muscle cells in bioreactors — essentially brewing meat instead of raising and slaughtering animals. Production costs have dropped dramatically — per GFI, the first cultured burger in 2013 “took months to produce and was reported to cost $330,000.” Today, optimistic projections suggest ~$63/kg (Garrison et al. 2022), with some companies claiming costs below $10/kg for pure cell mass (per a 2025 Lever VC industry report — note: authored by CM investors). These are costs for pure cultured cells, not finished consumer products, which may blend CM with plant-based or fungal ingredients at lower overall cost. This page explains the production process in detail and how each step affects costs. To explore these costs interactively, see our Monte Carlo cost model.

Cost Basis Matters: Read Carefully

Cost figures in the cultivated meat literature refer to different things depending on the study. Throughout this page, we label costs by their output basis where known:

  • Pure cell mass (wet weight): Cost to produce unprocessed cells in a bioreactor — this is what our dashboard model estimates
  • Cultivated ingredient: Cell mass after downstream processing (washing, concentration)
  • Hybrid product: A blend of cultivated cells with plant-based or other ingredients (e.g., 50/50 cultivated/plant-based)
  • Retail-equivalent product: Final consumer product including packaging, distribution, margins

A $14/kg figure for pure cell mass and a $14/kg figure for a 50/50 hybrid imply very different costs for the cultivated component. We try to flag the basis for every number cited below. See our TEA comparison page for a systematic breakdown.

The diagram below shows the high-level production flow. Each term is explained in detail in the sections that follow: Cell BankSeed TrainProductionHarvest → Processing → Product.

Cell Banking Frozen starter cells Seed Train Scale up in small reactors Production Large bioreactors Harvest Separate cells from media Processing Form into products 🍗 Chicken

Why Chicken?

Several factors make chicken an attractive first target for cultured meat:

Factor Advantage Source
Cell biology Chicken satellite cells can be cultured effectively and show robust viability Kim et al. 2024
Spontaneous immortalization Some avian cells can divide indefinitely without genetic modification — a rare spontaneous mutational event (a few cells acquire random mutations enabling indefinite division) that avoids GMO concerns Pasitka et al. 2022
Market size Chicken is the most consumed meat globally (~130 million tonnes/year) FAO 2023
Animal welfare ~70 billion chickens slaughtered annually vs ~300 million cattle FAO 2023, Rethink Priorities
Growth factors Similar FGF-2/IGF-1 requirements to bovine (~10-100 ng/mL optimal) Ahmad et al. 2023

Step 1: Cell Banking

Estimated cost share: <1% of total production cost at scale

What Happens

A cell bank is a frozen inventory of starter cells that can be thawed and expanded for production. These cells are taken from a living animal (via biopsy) or from tissue at slaughter (more common at scale) — and from cell lines that have been immortalized for continuous growth. Cell banking follows standard biopharmaceutical protocols for master and working cell banks (Baust et al. 2016, GFI Technical Overview).

The diagram below shows the four steps of cell banking: (1) take cells from a living animal (biopsy) or from tissue at slaughter; (2) isolate cells — a tissue sample contains many cell types tangled together, so we use enzymatic digestion to separate individual cells from the tissue matrix; (3) expand the isolated cells by growing them in culture; (4) freeze them via cryopreservation (-196°C) for long-term storage.

1. Biopsy Small tissue sample from live animal 2. Isolate Cells Enzymatic digestion 3. Expand Grow to billions 4. Freeze -196°C in liquid nitrogen

Cell Types Used

Cell Type Description Pros Cons Source
Satellite cells (myoblasts) Muscle stem cells that differentiate into muscle fibers Natural muscle tissue, good texture Limited doublings (~50-80 before senescence) Ding et al. 2018
Immortalized lines (spontaneous) Cells that spontaneously acquired random mutations enabling indefinite division — no intentional genetic modification No GMO concerns; no senescence; can be highly consistent when well-characterised (see Pasitka et al.) Rare mutational event; non-avian species rarely achieve this spontaneously; line characteristics must be verified Pasitka et al. 2022
Immortalized lines (gene-edited) Cells genetically engineered to divide indefinitely Consistent, scalable, no senescence, applicable to many species Regulatory complexity, GMO labeling in some markets Riquelme-Guzman et al. 2024
iPSCs Induced pluripotent stem cells Can differentiate into many cell types Complex differentiation protocols; limited in practice to certain lineages Choi et al. 2022
Embryonic stem cells (ESCs) Naturally immortal pluripotent cells from embryos Naturally immortal, broad differentiation potential Ethical and consumer acceptance concerns; regulatory complexity

Cost Impact

Cell banking is a one-time setup cost that’s amortized over many production runs.

Think of it like this: - Initial cost: $50K-$500K to establish and characterize a cell bank - Cells produced: Billions of cells per vial, hundreds of vials per bank - Production supported: Each bank can support thousands of production batches

If a bank costs $200K and supports 10,000 batches of 1,000 kg each, the per-kg cost is: $200K ÷ 10M kg = $0.02/kg

This is negligible compared to media costs ($5-50/kg) and CAPEX ($2-10/kg). Cell banking typically represents <1% of total production cost at scale.

The cells aren’t “used up” in the traditional sense — each frozen vial is thawed and expanded by ~10 billion-fold before production. A well-characterized cell bank is specifically designed to maintain consistent performance across all vials; that’s the point of the banking system. Replacement is needed primarily when vials run out or when cells reach their doubling limit — relevant only for non-immortalized lines. A well-characterised cell bank is specifically designed so performance does not degrade; that consistency is the whole point of the banking system.

A well-characterized cell bank can support years of production (GFI 2021).

The Hayflick limit (doubling limit) of cells matters for cell banking logistics and cost, though the per-kg impact at scale is small (<1% of total):

  • Primary satellite cells can only double ~50-80 times before senescing (Hayflick 1965, Nature 2025). These are typically adult stem cells taken from tissue.
  • This means you need frequent cell bank renewals (new biopsies, characterization, validation)
  • Immortalized lines — where adult stem cells (or occasionally other cell types) have been made to divide indefinitely, either through spontaneous random mutations or targeted gene editing — eliminate this constraint. One cell bank can theoretically last indefinitely.
  • Trade-off specific to gene-edited immortalized lines: may require GMO labeling and regulatory scrutiny. Spontaneously immortalized lines carry no intentional genetic modification and avoid this concern.

Cost implication: If a cell line can produce 10× more batches before replacement, your per-batch cell banking cost drops by 10×.


Step 2: Seed Train (Scale-Up)

Estimated cost share: ~5-10% of total production cost (mostly labor)

What Happens

Cells are progressively expanded from small flasks to larger and larger bioreactors, typically increasing volume by ~10× at each step:

The diagram shows the typical progression: vial → T-flask (flat bottle for early culture) → spinner flask (small stirred vessel) → progressively larger bioreactors. Cell counts grow from millions (10⁶) to hundreds of billions (10¹¹+). Timeline shows typical days in culture.

Seed Train: Progressive Scale-Up Vial 1 mL 10⁶ cells T-Flask 100 mL 10⁷ cells Spinner 1 L 10⁸ cells Small Reactor 10 L 10⁹ cells Medium Reactor 100 L 10¹⁰ cells Production 1,000+ L 10¹¹+ cells Day 0 Day 3 Day 6 Day 9 Day 12 Day 15+

Cost Impact

The seed train phase typically represents 5-15% of total production cost at scale. Per Humbird 2021: at 100 kTA scale, labor costs are “$1/kg wet cell mass” and consumables another “$1/kg”:

  • Uses expensive, small-scale equipment (research-grade, often single-use)
  • Requires manual handling and skilled labor ($50-150/hour fully loaded)
  • Consumes high-quality media (often pharma-grade at $5-20/L, though many companies now use food-grade at $0.50-2/L)

Increasingly, no. While early R&D relied heavily on pharma-grade media and equipment, most companies scaling up have transitioned to food-grade alternatives. Per a 2025 industry report:

  • Media: “costs $1 per liter or less and several are under $0.50 per liter” — “10-30× cheaper than [Humbird 2021] thought possible”
  • Equipment: Vow built a 20,000L bioreactor “well under $1 million” (80% below off-the-shelf costs)
  • Cell density: Companies achieving “60-90 g/L” vs Humbird’s 60 g/L maximum projection

Per the same report, production COGS for cell mass are claimed to be “$10-15/kg, with some leading-edge companies claiming costs below $10/kg” — up to 50% lower than the 2021 projections. Note: these claims come from a Lever VC report authored by CM investors and have not been independently verified.

Cell density is one of the most important parameters for cost. Note: density is measured in wet-weight (g/L); water content at harvest is typically ~75–90% depending on cell line, process, and post-harvest separation — we use 80% as a reference. Published TEAs often don’t state this assumption explicitly, which can make cost comparisons subtly inconsistent.

Density Media needed for 1 kg meat Relative media cost Est. media cost/kg (at $1/L)
30 g/L 33 liters 100% (baseline) ~$33/kg
100 g/L 10 liters 30% ~$10/kg
200 g/L 5 liters 15% ~$5/kg

Higher density means:

  • Less media per kg of meat (biggest savings)
  • Fewer reactor transfers in seed train
  • Smaller bioreactors needed for same output
  • Lower labor per kg

Current densities: 30-50 g/L (fed-batch), 60-90 g/L (commercial per 2025 industry report), up to 360 g/L in perfusion/continuous (PMC 2025)

The table above assumes media cost per liter ($/L) stays constant as density increases. In practice, this may not hold — particularly in nutrient-depleted fed-batch systems. Cell density in fed-batch mode is ultimately limited by how many grams of nutrients cells can extract from the available media volume; achieving higher densities requires proportionally richer (and more expensive) formulations. The per-kg cost benefit of higher density can therefore be partially offset by the richer media needed to sustain it.

In perfusion mode this coupling is weaker: fresh media is continuously supplied, so density is limited more by oxygen transfer and shear stress than by nutrient depletion per se. In continuous mode it varies with the recycling fraction.

The practical implication: combining very low \(/L with very high density in the same cost scenario may overstate savings. Our [cost model](index.qmd) samples these as somewhat independent parameters within process-mode-specific ranges — a simplification flagged on the [model limits page](limits.qmd#parameter-grounding). In the beliefs form we ask for **total media cost per kg of biomass** (\)/kg) rather than $/L and density separately, precisely because these aren’t independent — a knowledgeable respondent will naturally integrate the interaction.


Step 3: Production Bioreactors

Estimated cost share: 15-35% of total production cost (bioreactor CAPEX + buildings)

The Core Technology

Production-scale bioreactors are the heart of cultured meat manufacturing. They must:

  1. Maintain sterility — Any contamination means losing the entire batch ($100K-$1M+ loss per batch in biopharma; see Kelley 2009, Cytiva)
  2. Supply oxygen — Cells need O₂ but are shear-sensitive
  3. Remove CO₂Metabolic waste that acidifies media
  4. Control temperature — Typically 37°C ± 0.5°C for mammalian cells (avian cells similar)
  5. Provide nutrients — Via media perfusion or fed-batch feeding (see detailed comparison below)

The diagram below shows a standard stirred-tank bioreactor. Key components: the impeller (rotating blades that mix the culture), the sparger (bubbles oxygen into the media), and ports for adding media and harvesting cells.

Stirred-Tank Bioreactor Motor Key Components Impeller (mixing) Sparger (O₂ in) Media Cells 37°C, pH 7.2-7.4 Media in → Harvest →

Bioreactor Types

Different bioreactor designs make different trade-offs between cost, scale, and cell type compatibility. Most cultured meat R&D currently uses stirred-tank reactors (the pharmaceutical industry standard), but companies are actively developing custom food-grade designs to reduce costs.

The industry hasn’t converged on a single design yet. Key factors:

  • Stirred-tank: Proven, well-understood, but expensive. Used by most companies today.
  • Air-lift: Gentler on cells, potentially cheaper, but less established.
  • Packed-bed: Required for structured products (steaks), but harder to scale.
  • Custom food-grade: Already in use by some companies (e.g., Vow) — the key question is whether sterility can be maintained at scale.

Companies like UPSIDE Foods and Believer Meats have built large-scale facilities using modified pharma equipment, while others (Vow, etc.) are now operating custom food-grade bioreactors at substantially lower cost.

Type Description Scale Cost Range Source
Stirred-tank Traditional design with impeller mixing 1-20,000 L $50-500/L (pharma) Humbird 2021
Air-lift Bubbles provide mixing and oxygenation 1-50,000 L $30-200/L GFI 2021
Packed-bed Cells grow on scaffolds, media flows through 10-1,000 L $100-300/L Allan et al. 2019
Custom food-grade Simplified designs inspired by food/beverage industry 1,000-100,000 L $10-50/L (target) Risner et al. 2021

Bioreactor CAPEX accounts for roughly 15-35% of total production cost at scale, making it a pivotal cost driver. Pharma-grade stainless steel bioreactors cost $50-500/L installed (Humbird 2021, PMC 2024).

The opportunity — already being realized: Several companies are now using simplified food-grade designs (similar to beer brewing at $5-15/L). Vow (Australia) has built custom food-grade bioreactors at ~80% below pharma costs, and other companies are following suit. If this approach scales successfully, equipment costs could drop by 10x industry-wide.

Equipment Type Cost per Liter Example Industry
Pharma-grade bioreactor $50-500/L Vaccine production
Food-grade fermentation $10-50/L Specialty ingredients
Beer brewing tanks $5-15/L Craft breweries

Key question: Can cultured meat production maintain sterility and consistency with simpler equipment? This depends on whether the process can tolerate: - Less precise temperature control - Simpler cleaning validation - Lower-grade materials (304 vs 316L stainless)

Contamination is a real risk: Per a 2024 industry survey, cultivated meat companies reported an average microbiological batch failure rate of 11.2% (climbing to 19.5% at commercial scale). Primary contamination vectors included improper equipment sterilization and exposure during cell harvest. By comparison, the biopharmaceutical industry experiences contamination failures in only ~3.2% of batches at commercial facilities. This helps explain why many cultured meat companies have historically relied on pharma-grade equipment, though the trend is shifting: companies like Vow and others are now building custom food-grade bioreactors at substantially lower cost (per a 2025 Lever VC report, Vow built a 20,000L bioreactor “well under $1 million,” 80% below off-the-shelf costs).

Fed-Batch, Perfusion, and Continuous: Three Operating Modes

TL;DR: Fed-batch mode (fill with concentrated nutrient supplements, grow, harvest) achieves 5–30 g/L density at lower cost. Perfusion mode (continuous fresh media flow with cell retention) achieves 30–150+ g/L but uses more media. Continuous mode (also called chemostat-style: continuous feed and harvest) reaches 50–200 g/L with potentially lower media-use multipliers via recycling. The choice maps directly to the media-use multiplier parameter in our cost model. Values below 1 are discussed in the next section.

The choice of operating mode is not about different bioreactor types — it is about how nutrients are delivered and waste removed within the same basic stirred-tank reactor. This choice significantly affects achievable cell density and economics.

  • Fed-batch mode: Fill → Supplement as needed → Grow → Harvest all. Simple to operate; density 5–30 g/L; media multiplier ~1.
  • Perfusion mode: Continuous flow of fresh media in, spent media out, cells retained. Density 30–150+ g/L; media multiplier ~1–5.
  • Continuous mode: Continuous feed and continuous cell harvest. Density 50–200 g/L; media multiplier ~0.5–3 (lower with recycling).

The diagram compares two of the three operating modes. Fed-batch (left) harvests everything at once; perfusion (right) continuously adds fresh media and removes spent media while retaining cells. Continuous mode (not shown) simultaneously feeds fresh media and harvests cells to maintain steady-state density.

Fed-Batch Mode Fill Grow Harvest all ✓ Simple operation ✗ 5-30 g/L density Media multiplier ≈ 1 Perfusion Mode Fresh media Spent media Harvest cells ✓ 100-200+ g/L density ✓ Continuous production ✗ Complex operation Higher media usage

The media-use multiplier parameter in our interactive model captures this regime, and a few others:

  • Multiplier ≈ 1: Fed-batch mode (one reactor fill per kg of cells)
  • Multiplier ≈ 1–5: Standard perfusion
  • Multiplier ≈ 0.5–3: Continuous mode (lower with media recycling)
  • Multiplier < 1: Fed-batch with concentrated feeds, media recycling, or harvest concentration — see the three mechanisms below
  • Multiplier 5–10: Heavily media-intensive perfusion (stress-test region, outside our default)

The media-use multiplier: why values below 1 are physically meaningful

The cost model computes liters of media per kg of cells as:

\[L_{\text{per kg}} = \underbrace{\frac{1000}{\text{density (g/L)}}}_{\text{nominal reactor-fill volume}} \times \underbrace{\text{multiplier}}_{\text{effective fresh-media factor}}\]

At 50 g/L density the nominal reactor-fill volume is 20 L/kg — “one reactor filling, containing 1 kg of cells at 50 g/L.” At 100 g/L it’s 10 L/kg. A multiplier of 1 means you consumed exactly that much fresh media. Values above 1 are straightforward: perfusion systems continuously flow fresh media through, and over a batch you cumulatively use several reactor volumes. Values below 1 feel surprising at first but correspond to three very real mechanisms.

1. Media recycling. Spent media can be filtered (e.g., by tangential flow filtration), depleted nutrients replenished, and fed back into the reactor. If you recover and reuse 50% of your spent media, your net fresh media consumption per kg of cells is half the nominal reactor volume — multiplier ≈ 0.5. Aggressive recycling is cited in GFI’s 2025 review as likely necessary for reaching commercially viable cultivated-meat costs.

2. Fed-batch with concentrated feeds. Instead of flowing large volumes of dilute fresh media through the reactor, you start at a fraction of the working volume with full-strength media and then add small volumes of concentrated glucose / amino-acid / buffer solution as cells consume substrate. The total liquid media consumed over the run can be less than one nominal reactor volume, because most of the added mass is dissolved solute rather than water. Industrial microbial fermentation has been run this way for decades; for cultivated meat it maps to multipliers of ≈ 0.6–0.9.

3. Harvest-side cell concentration. If cells are concentrated after they finish growing — via settling, centrifugation, or filtration — you can extract 1 kg of cells from less media than 1000 / (growth density) suggests. For example, running the reactor at 50 g/L growth density but harvesting a 200 g/L slurry means you’re pulling 1 kg of cells out of 5 L of media, not 20 L. The baseline formula doesn’t have a separate knob for harvest concentration, so the multiplier absorbs that correction — values around 0.25–0.5 can appear this way without any recycling or fed-batch logic.

Why the model’s default range includes values below 1

The GFI 2023 recombinant-protein report assumes 8–13 L media per kg of meat as its cost-competitive scenario. Our dashboard lets you push cell density up to ~90 g/L. At 90 g/L:

\[\text{nominal L/kg} = \frac{1000}{90} \approx 11.1 \text{ L/kg}\]

So to hit the GFI upper bound of 13 L/kg at 90 g/L, you need multiplier ≈ 1.17. To hit the lower bound of 8 L/kg at 90 g/L, you need multiplier ≈ 0.72. At a more typical 60 g/L density, the nominal is 16.7 L/kg, and GFI’s 8–13 L/kg implies multipliers of 0.48–0.78. None of those scenarios are reachable with a floor of 1.0 — no matter how high cell density goes. That’s why the model’s default sampling range is now 0.5–3.0 rather than the earlier 1–10.

Values above 5× remain plausible for heavily media-intensive processes but are no longer part of the default sampled range; treat them as stress tests for pessimistic scenarios.

What this does NOT mean

  • It does not mean less than one reactor-filling’s worth of liquid physically entered the vessel. It means less than one nominal reactor-filling-equivalent of fresh media was consumed, once recycling, concentration, and fed-batch feed schedules are all counted as they affect the $/kg cost calculation.
  • It does not mean perfusion systems are being misrepresented — a perfusion reactor with aggressive media recycling can legitimately operate at an overall multiplier below 1 even though its instantaneous media-change rate is above 1.
  • The model uses a single bundled parameter rather than separate knobs for turnover, recycle fraction, and harvest concentration. That’s a simplification; a future revision may split them.
Cell densities have improved dramatically
  • 100-200 g/L: Demonstrated in perfusion systems (Clincke et al. 2013, Xu et al. 2023)
  • 360 g/L: Per PMC 2025: “harvested…cultured fat at 360 g/L” with “1.5 years of continuous culture and over 600 cell divisions”
  • 1.3 x 1011 cells/L: Believer Meats 2024 study using $0.63/L media, achieving $6.20/lb (~$13.67/kg) cultivated chicken
Factor Fed-Batch Perfusion Continuous
Cell density 5–30 g/L 30–150+ g/L 50–200 g/L
Media multiplier ~1 (or 0.5–0.9 with concentrated feeds) ~1–5 standard ~0.5–3 (lower with recycling)
Equipment Simplest More complex (ATF pumps, retention filters) Moderate (continuous feed/harvest pumps)
Contamination risk Lower (closed system, batch cycles) Higher (more connections, continuous operation) Moderate
Cycle time 5–10 days per batch Continuous (weeks–months) Continuous (steady-state)

These distinctions are simplifications. In practice, density, media-use multiplier, and recycle fraction are interdependent. Our dashboard model samples these parameters separately with process-mode-specific distributions; see Technical Reference for how they interact in the cost equations.

Per Humbird 2021: fed-batch achieves $37/kg wet cell mass (or $22/kg with hydrolysates), while perfusion costs $51/kg wet cell mass due to higher CAPEX ($23/kg capital charge) and consumables (ATF membranes at $16k each, 20 per bioreactor per year). Perfusion’s higher density doesn’t always offset equipment costs at current scales. Note: Humbird models generic mammalian cells, not chicken specifically.


Media Composition: 40-70% of Total Cost

Estimated cost share: 40-70% of total production cost — the single largest cost component

Media composition isn’t sequential — it’s used throughout the production process (in seed train and production bioreactors). We cover it separately because understanding media costs is essential for understanding overall economics.

Cell culture media contains everything cells need to grow. Below are components ordered by approximate share of total media cost at production scale.

Note on the interaction with cell density: Media cost per liter (\(/L) and cell density (g/L) are connected — they are not parameters you can optimise independently. Richer media formulations are often needed to sustain higher cell densities, because cells in denser cultures consume proportionally more amino acids, glucose, and other nutrients. The economically meaningful unit is therefore **media cost per kg of cells produced** (\)/kg), which reflects both $/L and the litres consumed per kg output. See the cell density section above and the model limits page for further discussion.

Component % of Media Cost Function Key Cost Driver
Amino acids 30-50% Building blocks for proteins Hydrolysates vs. pharma-grade
Growth factors 5-60%* Signaling proteins (FGF, IGF, TGF-β) Multiple strategies in development
Glucose 5-15% Energy source Commodity (~$0.50/kg)
Vitamins 3-8% Metabolic cofactors B-complex, etc.
Lipids 2-5% Cell membrane building ~$0.10-0.50/L
Minerals/salts 1-3% Osmotic balance, enzyme function Cheap (<$0.10/L)

Components above are listed by approximate share of media cost (largest first). The bottom three (vitamins, lipids, minerals) together account for only ~5-15% of media cost and are already available at commodity prices — they are not significant cost drivers.

*Growth factor share varies enormously: at research scale GFs can be 55-95% of media cost (Specht 2020). At production scale, projections range from 5-60% depending on technology assumptions — potentially <5% if breakthrough technologies succeed. Based on multiple TEA analyses, this appears to be one of the larger uncertainties in cultured meat economics.

At production scale, media (including growth factors) typically represents 40-70% of total production cost. Per PMC 2024: “The culture medium represents the most significant cost in CM production, accounting for 55%–95% of total expenses” at current scales. At optimized scales, this drops to 40-70% (Humbird 2021, Risner et al. 2021, GFI 2024).

Cost Component Share of Total Humbird 2021 $/kg
Media (all components) 40-70% $22/kg (or $6 with hydrolysates)
Capital costs (bioreactors) 15-35% $12/kg
Fixed OPEX (labor, overhead) 10-25% $3/kg
Downstream processing 2-15%

This is why media cost reduction (hydrolysates, cheap growth factors, high cell density) is so critical.

All commercial cultured meat now uses serum-free media — no current-paradigm cost trajectory depends on fetal bovine serum (FBS).

Until ~2018, animal cell culture relied on fetal bovine serum ($200–1,000/L), a complex mixture collected from bovine fetuses at slaughter. FBS was the universal cell-culture supplement — used across chicken, cow, pig, and fish work — because it contains hundreds of beneficial proteins (growth factors, albumin, attachment proteins, hormones).

It was abandoned for cultured meat for three reasons that all point the same direction:

  • It can’t scale. Global FBS supply is ~500,000–800,000 L/yr (van der Valk et al. 2018). At ~100 mL FBS per kg of meat (10% supplementation), 1 Mt of cultured meat would need ~100 billion L/yr — roughly 200,000× existing supply.
  • It contradicts the welfare goal. FBS is collected from bovine fetuses when pregnant cows are slaughtered (~1M+ fetuses/yr per PMC 2014).
  • It’s expensive and inconsistent. Batch-to-batch variability and $200–1,000/L pricing make it unworkable for commodity production.

All approved cultured meat products to date (UPSIDE Foods, GOOD Meat) use serum-free formulations. For cost modeling, FBS should be treated as historical context, not a current cost line.

Why this matters for understanding hydrolysates and growth factors:

FBS-based culture — one input

A single biological fluid provided everything cells need:

  • Amino acids & nutrients (basal nutrition)
  • Growth factor signalling (FGF-2, IGF-1, TGF-β)
  • Hormones, lipids, attachment proteins

Why abandoned: can't scale, slaughterhouse-derived, inconsistent batch-to-batch.

Serum-free culture — two separate inputs

Two independent cost problems to solve:

  • Basal media — amino acids, glucose, vitamins
    ← this is what hydrolysates address (CM_12)
  • Recombinant growth factors — FGF-2, IGF-1, TGF-β
    ← separate cost line, separate solutions (CM_13)

Scalable and animal-free — but two distinct cost challenges.

Because FBS was doing both jobs in one fluid, switching to serum-free doesn’t solve one cost problem — it creates two distinct ones. Hydrolysates address only the basal media component (top left → top right). Growth factors remain a separate challenge regardless of what you use for basal media.

Hydrolysates: The Big Win for Amino Acids

Important

Hydrolysates address basal media amino acids — not growth factors. These are basically separate cost categories. Hydrolysates can improve overall cell nutrition and may modestly reduce the amount of growth factor stimulation cells need, but they cannot replace growth factor signalling (FGF-2, IGF-1, TGF-β). The model tracks them on separate cost lines for this reason. See the before/after schematic in the FBS historical note above for why these are two independent problems.

Hydrolysates are enzymatically digested proteins from plants (soy, wheat) or yeast. They replace the amino acid fraction of media — typically 30-50% of media cost — and provide complete amino acid profiles at food-grade prices:

Media Type Cost ($/L) Source
Pharma-grade amino acids $1.00 - $4.00 Humbird 2021
Optimized serum-free (Beefy-R) $2.00 - $4.00 PMC 2025
Hydrolysate-based (optimized) $0.20 - $1.00 Believer 2024

Believer Meats, the company behind the Pasitka et al. 2024 chicken-specific TEA, shut down operations in late 2025. This is worth noting because their study provides some of the most optimistic (and the only chicken-specific) cost estimates in the literature. The shutdown likely reflects a combination of factors — capital constraints during the 2023-2025 VC pullback from alt-protein, timeline/investor mismatch, and possibly scale-up challenges — rather than a direct falsification of their published engineering estimates. We treat their technical results as still informative but factor the shutdown into our uncertainty about near-term achievability of their projected costs. See the TEA comparison page for more context.

To convert media cost per liter to cost per kg of cell biomass, you need to know the cell density and media turnover:

\[\text{Media cost per kg} = \frac{\text{Media cost (\\$/L)} \times 1000}{\text{Cell density (g/L)}} \times \text{turnover multiplier}\]

Cell Density Turnover Media at $1/L Media at $0.50/L
30 g/L (fed-batch) 1.0× $33/kg $17/kg
60 g/L (perfusion) 1.5× $25/kg $12.5/kg
150 g/L (high-density perfusion) 1.0× $6.7/kg $3.3/kg
200 g/L (continuous) 0.8× $4/kg $2/kg

This is why cell density matters far more than media formulation price in the cost calculation. Halving the $/L has the same effect as doubling the density.

Important caveat — $/L is not enough: A $0.20/L formulation with low nutrient density may not outperform a \(0.50/L formulation that is more nutrient-dense, because cells may need to consume *more* volume of the dilute medium per kg of output. The economically meaningful metric is **\)/kg of cell biomass produced**, not $/L. TEAs that report only $/L without stating their assumed density and media consumption rate are hard to compare directly.

Note: Hydrolysate-based and pharma-grade media can achieve comparable cell densities in published studies, though hydrolysate performance can vary depending on source, lot, and formulation.

Most CM cost models — including this one — focus on (a) the price of media per liter, (b) how many liters of media are needed per kg of output, and (c) growth factor costs. What they largely ignore is feed conversion efficiency: how efficiently cells convert nutrient inputs (glucose, amino acids) into cell biomass.

Why this matters at scale: At low volumes, growth factors and media formulation dominate costs. At industrial scale with cheap commodity inputs, the limiting cost becomes the mass of amino acids and glucose needed to produce a kg of biomass. If cells convert inputs inefficiently (say, 5–10% kcal efficiency), the commodity cost of glucose and amino acids alone could set a meaningful floor on production costs, regardless of how cheap the formulation is per liter.

The metric: Feed conversion can be expressed as: - kcal:kcal — kilocalories of cell biomass produced per kilocalorie of nutrient input - DW:DW — grams of dry-weight cell biomass per gram of dry-weight nutrient consumed

Published values for mammalian cell cultures in bioreactors are not widely reported, but conversion efficiencies are generally lower than for microbial fermentation. Understanding this matters because a 5% efficient process needs 20× more nutrient mass than a 100% efficient one — and at commercial volumes, the commodity cost of those nutrients is non-trivial.

What’s missing from the model: This model does not currently include a feed conversion efficiency parameter. The media cost calculation implicitly captures some of this through the L/kg × $/L calculation, but it doesn’t separate nutrient density from water content and doesn’t let you reason about the amino-acid and glucose commodity cost floor directly.

We’d value expert input on expected feed conversion ratios for chicken cells at commercial scale, and whether this should be incorporated into the cost model. See the beliefs form Expert Distribution section (E7) for a discussion prompt.

Tip

Hydrolysates are a promising and widely-pursued cost reduction pathway. Per Humbird 2021: “Soybean meal pricing for animal feed is about $0.33/kg… a formulation of mixed amino acids from hydrolysis could cost as little as $1.60/kg.” At $2/kg hydrolysate, “the macronutrient contribution [is reduced] by almost $16/kg, bringing the total cost to $22/kg.” Multiple studies have validated hydrolysate use for muscle cell culture (Ahmad et al. 2023, Ng & Zheng 2024), and several companies report achieving hydrolysate-based media at $1/L or less.1


Step 5: Growth Factors — A Key Cost Driver

Estimated cost share: ~2-40% of total production cost (wide range — depends heavily on technology breakthroughs)

What Are Growth Factors?

Growth factors are signaling proteins that tell cells to proliferate and differentiate. They bind to cell surface receptors and trigger intracellular cascades:

Mechanism in one sentence: a growth factor protein binds a cell-surface receptor → intracellular signal cascade → gene expression telling the cell to divide. The SVG illustrating this was removed from this page in the Apr 2026 trim — it’s educational but not cost-relevant. (See any cell-biology textbook, or GFI’s growth factor primer.)

Key Growth Factors for Cultured Meat

Different growth factors serve different purposes in the cell lifecycle:

  • FGF-2: Keeps cells proliferating without differentiating (you want lots of cells first)
  • IGF-1: Promotes growth; also helps trigger differentiation into muscle
  • TGF-β: Triggers differentiation and ECM production
  • EGF: Additional proliferation signal

Are they all required? Not necessarily all four — formulations vary. But you typically need at least FGF-2 (for proliferation) and something to trigger differentiation (TGF-β or similar). The exact cocktail depends on cell type and process.

Usage: typically 10-100 ng/mL of each factor, refreshed as media is changed.

Factor Function Research Price Cost/kg meat (research) Production Target Cost/kg meat (target) Source
FGF-2 (bFGF) Proliferation, maintain stemness ~$50,000/g ~$50/kg $1-10/g ~$0.001-0.01/kg CEN 2023
IGF-1 Proliferation, differentiation ~$10,000/g ~$10/kg $1-10/g ~$0.001-0.01/kg Market data
TGF-β Differentiation, ECM production ~$1,000,000/g ~$1,000/kg $10-100/g ~$0.01-0.10/kg GFI 2021
EGF Proliferation ~$5,000/g ~$5/kg $1-10/g ~$0.001-0.01/kg Market data

Cost/kg meat estimates assume ~50 ng/mL usage concentration and ~20 L media per kg of output (at 50 g/L cell density). At higher densities (100+ g/L), media usage and GF costs per kg drop proportionally.

Why Are They So Expensive?

Current growth factors are produced for medical research markets where volumes are tiny (milligrams), purity requirements are extreme, and customers pay premium prices. Per GFI: “99% cost reduction may be required for some recombinant proteins compared to how they are currently produced for the biopharmaceutical industry.” To hit $10/kg meat with GFs at 10% of cost, “albumin would need to be produced at $10/kg, insulin and transferrin at $1,000/kg, and growth factors at $100,000/kg.”

Solutions Being Developed for All Expensive Growth Factors

The approaches below aim to reduce costs for all the expensive recombinant proteins above (FGF-2, IGF-1, TGF-β, EGF), not just one specific factor. Each approach could in principle produce any protein cheaply at scale.

Approach Mechanism Status Target Price Source
Precision fermentation E. coli/yeast produce GFs at scale Scaling up $10-100/g GFI 2024
Plant molecular farming Transgenic plants express GFs Pilots $1-10/g BioBetter
Autocrine cell lines Engineer cells to make their own GFs Proof of concept ~$0/g Stout et al. 2023
Small molecule substitutes Chemicals that activate GF receptors Research <$1/g Ahmad et al. 2023
Thermostable variants FGF2-G3 with 20-day half-life Commercial Reduces usage Enantis

Based on our analysis, growth factor costs appear to be one of the largest uncertainties in cultured meat economics. Here’s our reasoning:

Scenario GF Cost per kg meat Total cost impact
Breakthrough (any approach works) <$1/kg Likely negligible
Partial success $5-20/kg Significant but potentially manageable
Limited progress $50-100+/kg Could be prohibitive at scale

Why we frame this as “any one works”: The breakthrough technologies (precision fermentation, plant molecular farming, autocrine cell lines) are largely substitutes. If any one succeeds at scale, the problem is substantially addressed.

This reasoning underlies our model’s binary switch approach — though we acknowledge this is a simplification. Reality may involve partial successes or combinations of approaches.

See GFI’s analysis for detailed technical roadmaps on each approach.

Important caveat: a 2024 Nature Food scoping review of TEAs concluded: “TEAs published to date demonstrate that, under the current technological paradigm, CM is unlikely to be competitive with conventional meat.” However, the review notes that “scale-up feasibility may hinge on cost-saving areas such as use of plant-based media components, food-grade aseptic conditions and extensive scaling of related supply chains.”

Note on jurisdictional forks: the relevant GM restriction is primarily about gene-edited cells in the final product, not about how growth factors are produced. GFs produced by GM microorganisms are typically used as processing aids and are not subject to GM labeling requirements even in strict jurisdictions like the EU — so the cost of GF production via precision fermentation does not itself create a jurisdictional cost gap. The fork is more relevant if gene-edited cell lines (which may require GMO labeling) are used in the final product. Whether and how to fork CM_01 by regulatory environment is being discussed at the workshop.


Step 6: Harvest & Processing

Estimated cost share: 2-15% of total production cost (lower for unstructured products like nuggets)

Cell Harvest

After cells reach target density, they’re separated from the media using standard bioprocessing techniques (Rathore et al. 2020):

  • Centrifugation: Spin to separate cells (~$0.10-0.50/kg)
  • Filtration: Tangential flow filtration through membranes
  • Settling: Allow cells to settle naturally (slowest but cheapest)

Forming Product (Downstream Processing)

For unstructured products (ground meat, nuggets):

  • Mix cell paste with binders, fats, flavors
  • Form into shapes using standard food equipment
  • Minimal processing needed
  • Cost: ~$2-5/kg (Risner et al. 2021)

For structured products (chicken breast, steak):

  • Requires scaffolds or 3D printing to organize fibers
  • Cells must align into muscle-like structures
  • Much more complex
  • Cost: ~$5-20/kg additional (GFI 2021)
Note

Our model includes an optional “downstream processing” toggle that adds $2-15/kg for structured products.

Industry sources suggest most companies have moved away from scaffolding for first-generation products:

  • Cannot achieve required cell densities with scaffolds
  • Most companies targeting unstructured products (mince, nuggets) first
  • Academic papers continue publishing scaffolding research, but this may not reflect current industry direction

The model’s downstream processing toggle ($2-15/kg for structured products) should be treated as speculative for near-term projections. First commercial products are more likely to be unstructured or blended with plant-based ingredients.


Cost Breakdown Summary

This diagram summarizes the typical cost structure and key levers for reduction, drawing on the components explained above: media, growth factors, bioreactors, and cell density.

Typical Cost Breakdown ($/kg chicken) Variable Costs (Media, GFs, etc.): 40-70% Capital Costs (Bioreactors): 15-35% OPEX (Labor, Overhead, etc.): 10-25% Variable Cost Split Media 30-50% Growth Factors* Micros 5-15% Other 5-10% *0-60% depending on technology Key Cost Reduction Levers: Hydrolysates: lowers 30-50% of media cost Cheap GFs: lowers 50-90% of GF cost (PIVOTAL) High cell density: lowers 50-80% of media volume Food-grade reactors: lowers 50-80% of CAPEX Scale (larger plants): lowers 30-50% of fixed costs

Note: Cell density reduces media volume needed per kg, affecting the green (media) cost component. It does not directly relate to micronutrients (teal).

Source: Cost breakdown ranges from Humbird 2021, Risner et al. 2021, GFI 2021, updated with data from PMC 2024, Believer Meats 2024, and a 2025 industry report.

Many foundational TEA analyses in this field date from 2021 (Humbird, Risner et al., CE Delft, GFI). These remain widely cited because they established the analytical frameworks still in use. Where possible, we supplement with more recent data:

The field is evolving rapidly. If you know of newer sources we should cite, please add a Hypothesis comment!

Whether to specify CM_01 by jurisdiction (gene-editing-permissive vs restrictive markets, US vs EU vs Singapore) or stick with a global average is a workshop framing question — see the workshop discussion.


Further Resources

The full prioritized reading list lives on the workshop resources page. Three starting points:

For a side-by-side of how the major TEAs differ, see the TEA comparison page.


Tip

Return to: Interactive Cost Model | Technical details: Documentation | Workshop (May 2026)

Footnotes

  1. There is some disagreement here. GFI’s 2025 amino acid report notes that hydrolysates can be deficient in key amino acids and typically require supplementation or blending. Humbird (2021) describes hydrolysate suitability as requiring “further study.” We are investigating the latest evidence on this point and welcome feedback.↩︎